Improving Cancer Immunotherapies through Empirical Neoantigen Selection

Area of Science:

• Oncology
• Immunology
• Bioinformatics

Background:

• Neoantigens are crucial targets for cancer immunotherapy.
• Computational epitope prediction tools offer rapid neoantigen identification but suffer from significant inaccuracies.
• High false-positive and false-negative rates hinder the clinical translation of predicted neoantigens.

Purpose of the Study:

• To review ex vivo technologies for the biological validation of neoantigens.
• To enhance the empirical prioritization of neoantigens for cancer immunotherapy.
• To address the limitations of in silico neoantigen prediction methods.

Main Methods:

• Review of ex vivo experimental technologies.
• Analysis of methods for neoantigen identification and validation.
• Comparison of computational and biological approaches for neoantigen selection.

Main Results:

• Ex vivo technologies provide biological confirmation of neoantigens, improving accuracy.
• These methods help overcome the high error rates associated with purely computational predictions.
• Biological validation enables more reliable selection of neoantigens for therapeutic development.

Conclusions:

• Ex vivo technologies are essential for accurate neoantigen identification in cancer immunotherapy.
• Integrating biological validation with computational predictions optimizes neoantigen selection strategies.
• Improved neoantigen prioritization through ex vivo methods holds promise for advancing cancer treatment.